
MDAI Stock Forecast & Price Target
MDAI Analyst Ratings
Bulls say
Spectral AI is supported by a differentiated AI-enabled diagnostic platform that can objectively and immediately assess wound healing potential, with clinical studies showing improved efficiency and a large, under-penetrated advanced wound care market to address. FDA clearance for DeepView System for Burn Centers, Trauma Centers, and Emergency Departments de-risks commercialization, while BARDA’s ~$31.7M funding and support for ~30 systems, plus potential subsidy for ~140 more, strengthen early adoption and non-dilutive growth. Its license model could support recurring, high-margin revenue, and the ~125 burn centers and ~5,000 trauma and ED units in the US underscore a sizable ~$3.7B TAM with further upside from DeepView SnapShot M and future indications.
Bears say
Spectral AI is viewed negatively because its investment case remains highly dependent on a commercial launch of DeepView that has not yet been proven, while projected FY26-FY30 revenue growth of 110% CAGR rests on an aggressive adoption and reimbursement backdrop. The company’s estimated 2030 revenue of $18.5M and 5.5x NTM EV/Sales multiple also imply a valuation that is vulnerable if clinical and regulatory timelines slip or BARDA-related revenue comes in lower than expected. Its limited operating history, competition, cybersecurity risk, and potential need for additional capital further weaken the fundamental risk-reward profile.
This aggregate rating is based on analysts' research of Spectral AI Inc and is not a guaranteed prediction by Public.com or investment advice.
MDAI Analyst Forecast & Price Prediction
Start investing in MDAI
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Spectral AI Inc (MDAI) Forecast
MDAI Analyst Forecast & Price Prediction
Start investing in MDAI
Order type
Buy in
Order amount
Est. shares
0 shares